Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-6.97% $8.54
America/New_York / 9 sep 2021 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 234.86 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | N/A |
SharesOutstanding: | 27.50 mill |
Avg Daily Volume: | 0.529 mill |
RATING 2021-09-10 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 8.44 - 8.65 ( +/- 1.23%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-06-08 | Harshbarger Benjamin | Buy | 200 000 | Stock Option (right to buy) |
2021-06-02 | Callori Fred | Buy | 85 000 | Stock Option (right to buy) |
2021-06-02 | Violin Jonathan | Buy | 85 000 | Stock Option (right to buy) |
2021-06-02 | Clauser Noah | Buy | 600 000 | Stock Option (right to buy) |
2021-06-02 | Kishbauch Michael D | Buy | 100 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 86 transactions |
Buy: 7 288 895 | Sell: 328 827 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.54 (-6.97% ) |
Volume | 0.0989 mill |
Avg. Vol. | 0.529 mill |
% of Avg. Vol | 18.69 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.